PL3393510T3 - Szczepionka przeciwko wirusowi zika - Google Patents
Szczepionka przeciwko wirusowi zikaInfo
- Publication number
- PL3393510T3 PL3393510T3 PL16828746.4T PL16828746T PL3393510T3 PL 3393510 T3 PL3393510 T3 PL 3393510T3 PL 16828746 T PL16828746 T PL 16828746T PL 3393510 T3 PL3393510 T3 PL 3393510T3
- Authority
- PL
- Poland
- Prior art keywords
- zika virus
- virus vaccine
- vaccine
- zika
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
- C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202585 | 2015-12-23 | ||
EP16161068 | 2016-03-18 | ||
EP16176049 | 2016-06-23 | ||
EP16176025 | 2016-06-23 | ||
EP16182845 | 2016-08-04 | ||
PCT/EP2016/082664 WO2017109225A1 (en) | 2015-12-23 | 2016-12-23 | Zika virus vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3393510T3 true PL3393510T3 (pl) | 2023-06-26 |
Family
ID=57821924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16828746.4T PL3393510T3 (pl) | 2015-12-23 | 2016-12-23 | Szczepionka przeciwko wirusowi zika |
Country Status (19)
Country | Link |
---|---|
US (13) | US10744194B2 (pl) |
EP (8) | EP4218807A3 (pl) |
JP (1) | JP6949027B2 (pl) |
KR (1) | KR20180097558A (pl) |
CN (2) | CN108697785B (pl) |
AU (1) | AU2016375338B2 (pl) |
BR (1) | BR112018012873A2 (pl) |
CA (1) | CA3009278A1 (pl) |
DK (1) | DK3393510T3 (pl) |
ES (2) | ES2941967T3 (pl) |
FI (1) | FI3393510T3 (pl) |
HR (1) | HRP20230273T1 (pl) |
HU (1) | HUE061679T2 (pl) |
LT (1) | LT3393510T (pl) |
MX (1) | MX2018007627A (pl) |
PL (1) | PL3393510T3 (pl) |
SG (1) | SG11201805120YA (pl) |
SI (1) | SI3393510T1 (pl) |
WO (6) | WO2017109229A1 (pl) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895437B2 (en) | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
EA035921B1 (ru) * | 2015-07-16 | 2020-08-31 | Бхарат Байотек Интернэшнл Лимитед | Вакцинные композиции для профилактики арбовирусных инфекций |
HUE061679T2 (hu) | 2015-12-23 | 2023-08-28 | Valneva Austria Gmbh | Zika vírus vakcina |
CA3030154A1 (en) * | 2016-07-08 | 2018-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric dengue/zika viruses live-attenuated zika virus vaccines |
JP7301811B2 (ja) * | 2017-09-21 | 2023-07-03 | ヴァルネヴァ エスイー | 免疫原性チクングニアウイルスchikv-delta 5nsp3を含む医薬組成物を製造する方法 |
CA3081578A1 (en) * | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
CN107988239B (zh) * | 2017-11-29 | 2021-03-19 | 南方医科大学 | 一种寨卡病毒的重组基因及其制备方法和应用 |
SG11202003975WA (en) * | 2017-11-30 | 2020-06-29 | Takeda Vaccines Inc | Method for inactivating zika virus and related methods |
CN107904215B (zh) * | 2017-12-27 | 2021-07-27 | 华农(肇庆)生物产业技术研究院有限公司 | 一种禽流感病毒的全悬浮培养方法 |
TWI658848B (zh) * | 2018-02-13 | 2019-05-11 | 國立清華大學 | 茲卡病毒疫苗組合物及其應用 |
CN110156880B (zh) * | 2018-02-13 | 2022-12-16 | 吴夙钦 | 兹卡病毒疫苗组合物及其应用 |
AU2019242601A1 (en) * | 2018-03-26 | 2020-11-12 | Boehringer Ingelheim Animal Health USA Inc. | Method of producing an immunogenic composition |
CN108676780B (zh) * | 2018-07-24 | 2021-08-10 | 华中农业大学 | 一种高效分离猪肠道冠状病毒的方法 |
CN109337876A (zh) * | 2018-10-15 | 2019-02-15 | 北京世纪元亨动物防疫技术有限公司 | 一种猪流行性腹泻病毒的纯化方法 |
EP3883961A1 (en) | 2018-11-20 | 2021-09-29 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
CN109627297B (zh) * | 2018-12-29 | 2022-06-14 | 复旦大学 | 来自寨卡病毒e蛋白的中和表位及其应用 |
AU2020211990A1 (en) * | 2019-01-22 | 2021-08-12 | 2Seventy Bio, Inc. | Methods and systems for manufacturing viral vectors |
EP3965811A1 (en) * | 2019-05-08 | 2022-03-16 | Takeda Vaccines, Inc. | Inactivated virus compositions and zika vaccine formulations |
EP4010015A1 (en) | 2019-08-09 | 2022-06-15 | Valneva SE | Chikungunya vaccine formulations |
AU2020328159A1 (en) | 2019-08-09 | 2022-01-27 | Valneva Se | Single shot Chikungunya virus vaccine |
WO2021048221A1 (en) | 2019-09-09 | 2021-03-18 | Valneva Austria Gmbh | Inactivation process for viruses |
KR102243295B1 (ko) * | 2019-11-15 | 2021-04-23 | 강원대학교산학협력단 | 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물 |
KR102365464B1 (ko) * | 2019-12-24 | 2022-02-22 | 강원대학교산학협력단 | 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법 |
WO2021158815A1 (en) * | 2020-02-05 | 2021-08-12 | New York Blood Center, Inc. | Zika virus immunogenic compositions |
EP3895729A1 (en) | 2020-03-01 | 2021-10-20 | Valneva Austria GmbH | Cpg-adjuvanted sars-cov-2 virus vaccine |
AU2021229710A1 (en) | 2020-03-01 | 2022-10-06 | Dynavax Technologies Corporation | CPG-adjuvanted SARS-CoV-2 virus vaccine |
MX2022010956A (es) * | 2020-03-03 | 2022-10-07 | Mayo Found Medical Education & Res | Polipeptidos del virus del zika. |
TW202203967A (zh) | 2020-04-06 | 2022-02-01 | 奧地利商瓦爾尼瓦奧地利有限責任公司 | 不活化SARS—CoV—2病毒疫苗 |
US20230324404A1 (en) | 2020-05-20 | 2023-10-12 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
US20230204567A1 (en) | 2020-05-20 | 2023-06-29 | Takeda Vaccines, Inc. | Method for determining the potency of antigens |
WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
WO2023148256A1 (en) | 2022-02-02 | 2023-08-10 | Valneva Austria Gmbh | Inactivated sars-cov-2 virus vaccine |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US86061A (en) * | 1869-01-19 | Improved horse-power | ||
EP1025209B1 (en) * | 1997-08-28 | 2007-02-28 | Cheil Jedang Corporation | An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine |
CA2341354C (en) * | 1998-09-02 | 2009-10-20 | The Government Of The United States Of America | Dengue viruses that are replication defective in mosquitos for use as vaccines |
AU2001275191A1 (en) | 2000-05-31 | 2001-12-11 | Chiron Corporation | Method for the purification of alphavirus replicon particles |
WO2002074963A1 (en) * | 2001-03-16 | 2002-09-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt | Dengue viruses that are replication defective in mosquitos for use as vaccines |
US7871814B2 (en) * | 2001-05-10 | 2011-01-18 | The Regents Of The University Of California | Recombinant bicistronic flaviviruses and methods of use thereof |
ATE485056T1 (de) | 2003-03-24 | 2010-11-15 | Intercell Ag | Verbesserte impfstoffe |
CN101516395B (zh) * | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
WO2009048633A2 (en) | 2007-10-11 | 2009-04-16 | The Board Of Regents Of The University Of Texas System | Chimeric chikungunya virus and uses thereof |
BRPI0910686A2 (pt) * | 2008-04-21 | 2015-09-29 | Tissue Regeneration Therapeutics Inc | células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos. |
SG171828A1 (en) * | 2008-11-26 | 2011-07-28 | Us Gov Health & Human Serv | Virus like particle compositions and methods of use |
WO2010085358A2 (en) * | 2009-01-23 | 2010-07-29 | The Board Of Regents Of The University Of Texas System | Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
EP3785730B1 (en) | 2011-12-06 | 2024-04-24 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
US9895437B2 (en) | 2012-04-18 | 2018-02-20 | Valneva Austria Gmbh | Aluminum compounds for use in therapeutics and vaccines |
WO2016145149A1 (en) | 2015-03-11 | 2016-09-15 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research | Combination purified inactivated vaccine for flaviviruses |
EA035921B1 (ru) | 2015-07-16 | 2020-08-31 | Бхарат Байотек Интернэшнл Лимитед | Вакцинные композиции для профилактики арбовирусных инфекций |
HUE061679T2 (hu) | 2015-12-23 | 2023-08-28 | Valneva Austria Gmbh | Zika vírus vakcina |
CN105749268B (zh) | 2016-04-11 | 2020-09-11 | 北京科兴中维生物技术有限公司 | 一种灭活的寨卡病毒疫苗 |
JP7301811B2 (ja) | 2017-09-21 | 2023-07-03 | ヴァルネヴァ エスイー | 免疫原性チクングニアウイルスchikv-delta 5nsp3を含む医薬組成物を製造する方法 |
-
2016
- 2016-12-23 HU HUE16828746A patent/HUE061679T2/hu unknown
- 2016-12-23 EP EP23152481.0A patent/EP4218807A3/en active Pending
- 2016-12-23 US US15/781,825 patent/US10744194B2/en active Active
- 2016-12-23 US US16/063,007 patent/US10639365B2/en active Active
- 2016-12-23 US US16/060,054 patent/US11331382B2/en active Active
- 2016-12-23 FI FIEP16828746.4T patent/FI3393510T3/fi active
- 2016-12-23 WO PCT/EP2016/082668 patent/WO2017109229A1/en active Application Filing
- 2016-12-23 EP EP16828745.6A patent/EP3393509B1/en active Active
- 2016-12-23 MX MX2018007627A patent/MX2018007627A/es unknown
- 2016-12-23 AU AU2016375338A patent/AU2016375338B2/en active Active
- 2016-12-23 JP JP2018532747A patent/JP6949027B2/ja active Active
- 2016-12-23 SI SI201631676T patent/SI3393510T1/sl unknown
- 2016-12-23 EP EP16826740.9A patent/EP3393507B1/en active Active
- 2016-12-23 HR HRP20230273TT patent/HRP20230273T1/hr unknown
- 2016-12-23 DK DK16828746.4T patent/DK3393510T3/da active
- 2016-12-23 WO PCT/EP2016/082663 patent/WO2017109224A1/en active Application Filing
- 2016-12-23 EP EP16826739.1A patent/EP3393506B1/en active Active
- 2016-12-23 KR KR1020187017319A patent/KR20180097558A/ko unknown
- 2016-12-23 WO PCT/EP2016/082664 patent/WO2017109225A1/en active Application Filing
- 2016-12-23 ES ES16828746T patent/ES2941967T3/es active Active
- 2016-12-23 US US16/062,245 patent/US10537630B2/en active Active
- 2016-12-23 WO PCT/EP2016/082666 patent/WO2017109227A1/en active Application Filing
- 2016-12-23 EP EP23219512.3A patent/EP4357355A2/en active Pending
- 2016-12-23 US US15/781,959 patent/US10660950B2/en active Active
- 2016-12-23 CN CN201680074939.XA patent/CN108697785B/zh active Active
- 2016-12-23 ES ES16826741T patent/ES2950887T3/es active Active
- 2016-12-23 EP EP23175136.3A patent/EP4253403A3/en active Pending
- 2016-12-23 CA CA3009278A patent/CA3009278A1/en active Pending
- 2016-12-23 PL PL16828746.4T patent/PL3393510T3/pl unknown
- 2016-12-23 EP EP16826741.7A patent/EP3393508B9/en active Active
- 2016-12-23 SG SG11201805120YA patent/SG11201805120YA/en unknown
- 2016-12-23 WO PCT/EP2016/082662 patent/WO2017109223A1/en active Application Filing
- 2016-12-23 BR BR112018012873-2A patent/BR112018012873A2/pt active Search and Examination
- 2016-12-23 LT LTEPPCT/EP2016/082664T patent/LT3393510T/lt unknown
- 2016-12-23 CN CN202210678575.3A patent/CN115381934A/zh active Pending
- 2016-12-23 EP EP16828746.4A patent/EP3393510B1/en active Active
- 2016-12-23 WO PCT/EP2016/082667 patent/WO2017109228A1/en active Application Filing
-
2019
- 2019-12-04 US US16/702,764 patent/US11207397B2/en active Active
-
2020
- 2020-03-10 US US16/813,862 patent/US11219681B2/en active Active
- 2020-04-06 US US16/840,760 patent/US11406700B2/en active Active
- 2020-07-13 US US16/927,086 patent/US11524064B2/en active Active
-
2021
- 2021-12-13 US US17/548,721 patent/US20220273786A1/en active Pending
-
2022
- 2022-07-06 US US17/811,059 patent/US20230056142A1/en active Pending
-
2023
- 2023-03-06 US US18/178,638 patent/US11951163B2/en active Active
- 2023-06-14 US US18/334,497 patent/US20240108712A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT3393510T (lt) | Zikos viruso vakcina | |
SG10201913630YA (en) | Zika virus vaccine | |
ZA201804071B (en) | Recombinant zika vaccines | |
HK1255847A1 (zh) | 針對乙型肝炎病毒的疫苗 | |
IL258831A (en) | Assemble respiratory syncytial virus | |
PT3718565T (pt) | Vacinas contra vírus respiratórios | |
HK1246183A1 (zh) | Hpv疫苗 | |
ZA201700165B (en) | Influenza virus vaccines and uses thereof | |
GB201518684D0 (en) | Vaccine | |
GB201613191D0 (en) | Zika virus vaccine | |
GB201406608D0 (en) | Virus | |
SG11201610443WA (en) | Influenza virus vaccines and uses thereof | |
GB201522132D0 (en) | Vaccine | |
GB201419572D0 (en) | Virus | |
GB201506041D0 (en) | Avian vaccine | |
PT3393510T (pt) | Vacina contra o vírus zika | |
IL249704A0 (en) | Influenza virus vaccines and their uses | |
IL249705A0 (en) | Influenza virus vaccines and their uses | |
GB201522013D0 (en) | Virus | |
GB201516936D0 (en) | Virus | |
GB201507419D0 (en) | Virus | |
GB201507529D0 (en) | Virus preparations | |
GB201406470D0 (en) | Virus | |
GB201408046D0 (en) | Virus preparations | |
GB201403582D0 (en) | Virus |